Prostamax

What it is

Prostamax is built from four amino acids in the sequence lysine, glutamic acid, aspartic acid, and proline. It belongs to a family of short bioregulator peptides that researchers describe as acting on specific tissues rather than the whole body; one small organ-culture study included prostate tissue among several organs tested.

The main line of research on Prostamax looks at its effect on chromatin, the tightly packed form DNA normally takes inside a cell's nucleus. Researchers report that it can loosen this packing, a process called deheterochromatinization, in blood cells taken from older people, which they propose could release some age-related silencing of genes.

How it is studied

Nearly all of the primary evidence for Prostamax comes from laboratory studies of chromatin structure in blood cells (lymphocytes) taken from elderly human donors, examined with genetic and biophysical methods. A separate, smaller study looked at its effect on organ tissue, including prostate tissue, grown in culture. No large-scale human clinical trial of Prostamax has been published in the sources reviewed for this entry.

What studies report

• In blood cells from people aged 75 to 88, Prostamax and several related short peptides caused the tightly packed form of DNA to loosen and activated genes that make the machinery cells use to build proteins, a pattern the researchers describe as reversing some age-related gene silencing. [1]
• In a more detailed follow-up study of blood cells from people aged 75 to 86, Prostamax changed several measures of chromosome structure, including raising the rate of a marker of DNA exchange between paired chromosomes and reducing large blocks of tightly packed DNA on two specific chromosomes. [2]
• A biophysical study of the same cell type found that Prostamax shifted the temperature at which parts of the DNA-protein packing structure came apart under heat, a technical sign the researchers linked to a partial loosening of that packing. [3]
• In a small organ-culture study, Prostamax and three other short peptides from the same research program each showed a stimulating effect on tissue explants taken from the organ they were designed for, including prostate gland tissue, in both young and aged rats. [4]

What is not known

Descriptions circulating outside the primary literature claim Prostamax was tested in animal models of prostate inflammation or enlargement, but no such study could be traced to a findable, peer-reviewed paper; those specific claims are not included here. Nearly all of the verified research on Prostamax comes from one overlapping group of researchers working in blood cell chromatin, so independent replication is limited, and no large human clinical trial exists. Whether the reported chromatin effect translates into any measurable outcome in living people, prostate-related or otherwise, has not been established.

Reported adverse findings

• The cell and tissue studies reviewed here reported chromatin structure and tissue-growth endpoints rather than a formal toxicity assessment; no adverse-event profile is described in the sources reviewed. [1][2][3][4]

Regulatory status

Prostamax has not been approved as a drug by the FDA or any other regulatory agency identified in the sources reviewed; against its sizeable cell-based research base, the published human clinical trial evidence is thin.